Successful treatment of disseminated human papillomavirus infection with pegylated interferon and ribavirin.
We report a case of disseminated human papillomavirus infection that developed in a patient while receiving efalizumab for the treatment of psoriasis. This infection progressed for several months after efalizumab treatment had been stopped. All human papillomavirus lesions completely resolved after 10 weeks of therapy with a combination of pegylated interferon and ribavirin.
Shrestha
Nabin K
NK
Department of Infectious Disease, Cleveland Clinic, Cleveland, Ohio, USA. shrestn@ccf.org
Hamrock
David J
DJ
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D008297:Male; D030361:Papillomavirus Infections / Q000188:drug therapy* / Q000209:etiology; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons; C472181:efalizumab